tecadenoson
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00713401)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Adenosine A1 receptorAGONIST
ADORA1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
OC[C@H]1O[C@@H](n2cnc3c(N[C@@H]4CCOC4)ncnc32)[C@H](O)[C@@H]1O- Mol. weight
- 337.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL392149 ↗
Also known as
- cvt 510
- cvt-510
- cvt-510
- cvt-510
- n-(3-tetrahydrofuranyl)-6-aminopurine riboside
- tecadenoson
- tecadenoson
- tecadenoson
- tecadenoson
- tecadenoson
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00713401 | Phase 2 | Feb 1, 2008 | Gilead Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1